Findings in a new comprehensive review uphold the research that has found CBD safe for human consumption.
Evidence indicates that cannabidiol (CBD), a natural non-psychoactive compound derived from cannabis plants like marijuana and hemp, is safe for human consumption, according to a new research review published in Cannabis and Cannabinoid Research.
A pair of investigators from Germany research center nova-Institut, Iffland Kerstin and Grotenhermen Franjo, set out to extend the findings of Mateus Machado Bergamaschi’s 2011 comprehensive survey on the safety and side effects of CBD. Bergamashi’s study had found controlled CBD to be safe in humans and animals. The new review confirmed those findings.
“This review could substantiate and expand the findings of Bergamaschi et al. about CBD favorable safety profile,” the review concluded.
Kerstin and Franjo’s review was meant to build on the studies mentioned in Bergamashi’s study and to update it with new findings since it was published. The investigators included both preclinical and clinical trials.
Studies indicate that CBD has no adverse physiological effect on blood pressure, heart rate, body temperature, glucose levels, pH, pressure exerted by carbon dioxide or oxygen, hematocrit, gastrointestinal transit, emesis, rectal temperature, or potassium and sodium levels. In one study, administering 60 mg/kg of CBD to mice three days per week for 12 weeks was found to have no adverse effects, including the ability to control bodily movements, rounding of the back, involuntary tremors, swaying gait, tail stiffness, urination, defecation, or vocalization behavior.
Even chronic use of CBD in humans has shown the cannabinoid to have no neurological, psychiatric, or clinical adverse effects. No respiratory depression or cardiovascular complications have been recorded.